Neurocrine biosciences presented baseline data from the cahtalyst™ program in cah and study data for modified-release hydrocortisone in primary adrenal insufficiency and cah at ece 2024

- cahtalyst™ phase 3 baseline characteristics highlight limitations of current cah treatment paradigm in children, adolescents and adults - phase 2 study for modified-release hydrocortisone in adults with adrenal insufficiency demonstrated participants achieved physiological morning cortisol levels after 4 weeks  - phase 3 extension study data for modified-release hydrocortisone in adults with cah demonstrated reduction in median daily hydrocortisone dose and an increase in responders at levels ≤ 25 mg/day     san diego , may 14, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) and diurnal ltd., a neurocrine biosciences company, presented baseline data from the cahtalyst™ phase 3 studies of crinecerfont in adult and pediatric patients with congenital adrenal hyperplasia (cah), and modified-release hydrocortisone (chronocort®) data for a phase 2 clinical study (champain) in participants with primary adrenal insufficiency and in a phase 3 extension study in cah.
NBIX Ratings Summary
NBIX Quant Ranking